PHAT Earnings

Quarterly EPS
$-1.32
Q3 2024
$-1.05
Q4 2024
$-1.31
Q1 2025
$-1.05
Q2 2025
$-0.41
Q3 2025
$-0.29
Q4 2025
$-0.37
Q1 2026
$-0.21
Q2 2026
Latest Revenue74.3M
Latest Net Income-17582000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.2174.3M-17582000+88.0%+80.0%
Q1 2026-$0.3758.3M-30369000+104.4%+71.8%
Q4 2025-$0.2957.6M-21148000+94.1%+72.4%
Q3 2025-$0.4149.5M-29973000+202.7%+68.9%
Q2 2025-$1.0539.5M-75810000+439.4%+32.7%
Q1 2025-$1.3128.5M-94316000+1,391.6%+7.7%
Q4 2024-$1.0529.7M-74451000+4,249.6%+23.9%
Q3 2024-$1.3216.4M-85577000-73.7%
Q2 2024-$1.567.3M-91446000
Q1 2024-$1.421.9M-82852000
Q4 2023-$1.38682.0K-79570000
Q3 2023-$0.76-43243000
Phathom Pharmaceuticals (PHAT) — Earnings